RNA Based Therapeutic Market growing significantly at 8.1% CAGR with $330.9 million by 2031

What are RNA-based therapeutics?

RNA therapeutics work by manipulating the expression and activity of specific target molecules, providing the means to treat diseases that do not respond to conventional drug types.

How big is the RNA therapeutic market? According to the report, the global RNA based therapeutics industry is expected to reach $25,121.95 million by 2030, having witnessed a value of $4,938.38 million in 2021, with a considerable CAGR of 17.6% from 2021 to 2030.

Key Takeaways:

• The RNA antisense segment to retain its lion’s share throughout the forecast period
• The genetic disorder segment to rule the roost by 2030

Request Sample Copy of the Report: 

https://www.alliedmarketresearch.com/request-sample/546

Major Factors Driving the Growth of RNA Based Therapeutic Market:

• Technological Advancements in RNA Therapeutics: Significant advancements in RNA technology, including the development of siRNA, miRNA, and antisense oligonucleotides (ASOs), have paved the way for novel RNA-based therapeutics. These advancements have enabled the targeting of specific genes and RNA molecules, leading to more precise and effective treatments.

• Rising Prevalence of Chronic Diseases: The increasing prevalence of chronic diseases, such as cancer, cardiovascular diseases, neurological disorders, and genetic disorders, is driving the demand for innovative treatment options. RNA-based therapeutics hold promise for treating a wide range of these conditions, offering hope for patients with limited treatment options.

• Success of RNA-Based COVID-19 Vaccines: The remarkable success of mRNA-based COVID-19 vaccines, such as those developed by Pfizer-BioNTech and Moderna, has propelled RNA therapeutics into the spotlight. This success has demonstrated the potential of RNA-based therapies and has boosted investor confidence in the field.

• Expanding Therapeutic Applications: The scope of RNA-based therapeutics is rapidly expanding beyond cancer treatment to encompass a wide range of therapeutic areas, including infectious diseases, autoimmune disorders, and rare genetic disorders. This expansion is opening up new avenues for drug development and driving market growth.

Market Segmentation:

By Type:

• RNA Interference (RNAi)
• RNA Antisense

By Application:

• Genetic Disorders
• Auto immune disorders

By End User:

• Research Institutes
• Hospitals & Clinics

By Region:

• North America (U.S., Canada, Mexico)
• Europe (Germany, France, UK, Italy, Spain, Rest of Europe)
• Asia-Pacific (Australia, Japan, China, India, South Korea, Rest of Asia-Pacific)
• LAMEA (Brazil, Saudi Arabia, South Africa, Rest of LAMEA)

Request for Customization: 

https://www.alliedmarketresearch.com/request-for-customization/546

Recent Developments in the RNA Based Therapeutics Market

• In June 2022, Alnylam Pharmaceuticals, Inc., one of the leading RNAi therapeutics company, announced that the U.S. Food and Drug Administration (FDA) approved AMVUTTRA (vutrisiran), an RNAi therapeutic administered via subcutaneous injection once every three months (quarterly) for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults.
• In December 2021, Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, and Qilu Pharmaceutical, one of the leading pharmaceutical companies in China, announced that the companies have entered into an exclusive licensing agreement and strategic partnership for the development and commercialization of AB-729 for the treatment of hepatitis B. AB-729 is Arbutus’s lead RNA interference (RNAi) therapeutic that is currently in multiple Phase 2a proof-of-concept clinical trials designed to evaluate it in combination with other approved or investigational agents.

Competitive Landscape:

• Gradalis, Inc.
• Arrowhead Pharmaceuticals
• Arbutus Biopharma Corporation
• Benitec Biopharma Inc.
• Silence Therapeutics plc
• Alnylam Pharmaceuticals, Inc.
• Genzyme (Sanofi)
• Ionis Pharmaceuticals
• Sarepta Therapeutics

Buy this Premium Research Report: 

https://www.alliedmarketresearch.com/purchase-enquiry/546

Key Questions Answered in the Intelligent Study

What is the market size and growth rate of the global and regional market by various segments?
What is the market size and growth rate of the market for selective countries?
Which region or sub-segment is expected to drive the market in the forecast period?
What Factors are estimated to drive and restrain the market growth?
What are the key technological and market trends shaping the market?
What are the key opportunities in the market?
What are the key companies operating in the market?
Which company accounted for the highest market share?

Why Choose Allied Market Research?

Industries’ Best Analysts
Exclusive Product Offerings
Customer Research Services
Dynamics Research Methodology
Comprehensive Reports
Latest Technological Advancements
Value Chain Analysis
Future Market Opportunities
Market Growth Dynamics
Quality Assurance
Post-sales Support
Continuous Report Update

Market Dynamics and Transformations

Economic Downturn Analysis: Impact of Recession in 2023
Pandemic’s Influence: Impact of Covid-19 Pandemic
Market Evolution: Recent Developments in the Market with Key Players Announcements

Comprehensive Healthcare Industry Research Studies:

Advanced Wound Care Market:

https://www.alliedmarketresearch.com/Advanced-Wound-Care-market

Analgesics Market: https://www.alliedmarketresearch.com/analgesics-market

Medical/Diagnostic Imaging Market: https://www.alliedmarketresearch.com/medical-diagnostic-imaging-market

Defibrillators Market: https://www.alliedmarketresearch.com/defibrillator-market

About Allied Market Research:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Wilmington, Delaware. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.